TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05724615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach + Bulk ordering
Description: Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance
Description: Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening. They will also receive text messages to remind them to have their lab completed as well as a link to schedule the lab and inform them of walk-in hours.
Study: NCT04712058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir / Emtricitabine / Tenofovir Alafenamide Oral Tablet [Biktarvy]
Description: Biktarvy will be administered on the same day of diagnosis. The daily dosing will be continued for 48 weeks.
Study: NCT05822388

Intervention type: PROCEDURE
Intervention: Deep Brain Stimulation Surgical Procedures as Part of Routine Clinical Care
Description: Participants in this study will already be undergoing a DBS intervention, however, this is part of their standard clinical care. Pre-surgical DBS candidates that enroll in this study will consent to participate in 1) pre-operative neuroimaging including a high-resolution MRI scan, 2) collection of pre-operative neurocognitive data via chart review and 3) a 1-year postoperative neurocognitive assessment.
Study: NCT05993923

Intervention type: OTHER
Intervention: GPOU
Description: Intervention upstream of the perioperative management according to the nutritional grade. Grade 4 Nutrition patients will be hospitalized earlier, i.e. 10 to 15 days before surgery for the start of artificial nutrition. A temporary return home can be organized with the supervision of a service provider until a second admission for surgical management. Grade 2 Nutrition patients will be called 24 to 48 hours before the surgical procedure.~Anticipation of discharge at admittance Early mobilization Comorbidity management Prevention of iatrogenia Management of geriatric frailties Daily medical and paramedical assessment Detailed discharge report
Study: NCT04891289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: See arm for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: See arm for details.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: See arm for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: See arm for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: See arm for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR)
Description: See arm for details.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanted Medical Device
Description: Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy
Study: NCT06537921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 200mg
Description: Dosage: 2x100mg/daily for 8 weeks
Study: NCT06542666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy
Description: The intervention focuses on addressing the maladaptive cognitive, physical, and lifestyle behaviors related to the disorder.~Cognitive functional therapy will focus on factors considered to contribute to the pain disorder, addressing the following topics:~1. The multidimensional nature of persistent pain, beliefs, emotions, and behaviors (movement and lifestyle) that can reinforce a vicious cycle of pain sensitization and disability.~2. Specific functional training designed to normalize maladaptive and provocative postural and movement behaviors as directed by the individual's presentation.~3. Targeted functional integration into daily activities that are avoided and/or provocative for the patient.~4. Counseling on physical activity and lifestyle, which will include promoting a gradual increase in physical activity based on the individual's preference and availability, advice on sleep hygiene, stress management strategies, and social re-engagement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Individuals allocated to this group will perform stretching and strengthening exercises. The self-stretching exercises will target the upper trapezius and posterior shoulder region. Each stretching exercise will be performed for 3 repetitions of 30 seconds, with an interval of 10 seconds between repetitions.~The strengthening exercises will be performed using resistance elastic bands. Three sets of 10 repetitions will be performed for each strengthening exercise, with 1 minute of rest between sets. The strengthening exercises will target the lower and middle trapezius, anterior serratus, and the external and internal rotators of the shoulder.
Study: NCT05700877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAC-based treatment strategy
Description: The intervention is a combination of screening with a heart CT scan and multifactorial intervention based on the screening results. Participants randomized to CAC-based treatment and with screening results showing high risk of CVD, will receive a multifactorial intervention including the combination of two open label investigational medical products: dapagliflozin 10mg/day and semaglutide 0.25 /week or 0.5 /week or 1.0 /week.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment
Description: Participants randomized to standard treatment are recommended to follow updated guidelines for CVD prevention.
Study: NCT06223685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifaximin 200 MG
Description: Dosage 3x2 tablets per day 14 days
Study: NCT06540430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Use of a Mobile Application for Stoma Self-Care
Description: The intervention group will use a mobile application where patients input their stoma condition, allowing healthcare professionals to monitor and manage their care. The app provides patients with information on diet, physical activity, stoma care, emotional support, and daily living needs.
Study: NCT06223685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 200 MG
Description: Dosage 3x2 tablets per day 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: 2x1 capsules per day. 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 2x1 capsules per day. 12 weeks.
Study: NCT05524779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-785-7
Description: Treatment with the BTL-785-7 applicator to the BTL-785F system.
Study: NCT04757402

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counselling with NSQIP Surgical risk calculator
Description: Use of NSQIP surgical risk calculator to check for patient satisfaction regarding pre operative counseling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counselling with NSQIP Surgical risk calculator
Description: Use of NSQIP surgical risk calculator to check for patient satisfaction regarding pre operative counseling.
Study: NCT05340309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab and Recombinant Human Hyaluronidase
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05439135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: washed microbiota transplantation
Description: Each patient will receive washed microbiota transplantation each day for three consecutive days. After WMT, participants will receive free diet plus home enteral nutrition (solution at a 750ml daily dosage that provides 750 kcal energy) at home for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: washed microbiota transplantation
Description: Each patient will receive washed microbiota transplantation each day for three consecutive days. After WMT, participants will receive free diet plus home enteral nutrition (solution at a 750ml daily dosage that provides 750 kcal energy) at home for 8 weeks.
Study: NCT05943886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.
Study: NCT06631235

Intervention type: OTHER
Group type: OTHER
Intervention: orthopedic appliance
Description: appliances are used to correct skeletal class II due to mandibular deficiency
Study: NCT05943886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.
Study: NCT06631235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aesthetic orthopedic appliance
Description: aesthetic appliances are used to correct skeletal class II due to mandibular deficiency
Study: NCT06213961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pecha kucha education
Description: Basic life support training to be given to students will be given by the pecha kucha presentation method.
Study: NCT05943886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.
Study: NCT06330506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure ulcer prevention pack
Description: The pressure ulcer prevention package to be prepared by the researchers will be applied
Study: NCT05943886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC88473 injection
Description: HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by subcutaneous injection in the abdomen.
Study: NCT04334993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Patients with high risk disease features after 2 induction blocks as defined per protocol will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation.
Study: NCT06554379

Intervention type: OTHER
Intervention: Periodontal health and gingivitis
Description: The presence or absence of periodontal disease in the gingiva was determined.

Intervention type: OTHER
Intervention: Periodontal health and gingivitis
Description: The presence or absence of periodontal disease in the gingiva was determined.
Study: NCT04756466

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
Study: NCT05069012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine is administered to provide pain relief after cesarean delivery; this is an assessment of the dose-response as measured by the duration of pain relief

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine is administered to provide pain relief after cesarean delivery; this is an assessment of the dose-response as measured by the duration of pain relief

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine is administered to provide pain relief after cesarean delivery; this is an assessment of the dose-response as measured by the duration of pain relief
Study: NCT04756466

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus
Description: Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
Study: NCT05244746

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: rectus sheath block
Description: blocking the nerve underneath the rectus muscle by bupivicaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rectus sheath block
Description: blocking the nerve underneath the rectus muscle by bupivicaine
Study: NCT04761133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine pleural irrigation
Description: Irrigation of the infected pleural cavity with an antiseptic solution to reduce microbial load
Study: NCT04851509

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Rotational Locking
Description: Performed, as per the Synthes technique guide, using the 5mm hex flexible set screwdriver and then loosening the set screw by one-half turn of the screwdriver.
Study: NCT01108913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimosiamose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04851509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static Locking
Description: Performed by using the torque-limiting set screwdriver and locking the set screw down onto the helical screw to prevent dynamic sliding of the screw within the nail.
Study: NCT06555952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MegaNatural-BP SR 150Mg Tablet
Description: GSE MegaNatural BP

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: given in place of GSE MegaNatural BP
Study: NCT05163548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerQseal Plus Device
Description: Percutaneous closure of femoral artery access site created by 14 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing Percutaneous Transcatheter procedures.
Study: NCT05248919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epclusa (nucleotide HCV NS5B polymerase inhibitors).
Description: Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epclusa (nucleotide HCV NS5B polymerase inhibitors).
Description: Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks
Study: NCT06173882

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ordinary moxibustion volume group
Description: Moxibustion for 10 minutes per acupoint

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: First group of heavy moxibustion
Description: Moxibustion for 20 minutes per acupoint

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Second groups of heavy moxibustion
Description: Moxibustion for 30 minutes per acupoint
Study: NCT04516356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Korean hand acupressure
Description: According to the working principle of Korean hand acupressure; There are active points and areas in the hands and feet that fit the whole body. The active points on the hands and feet are properly matched to reflect the anatomy of the whole organism. Areas in the body and systems suitable for them are in constant contact. In the patient, the signal wave moves from the damaged point or area and reaches the appropriate point immediately. Thus, changes such as severe pain, skin discoloration, hardening, thickening and thinning in some parts of the skin occur at that point. With the stimulation of the effective point, a treatment wave occurs that heals the sick organ.
Study: NCT05053594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine 10 mcg/kg
Description: Once the third response to TOF is obtained, neostigmine 10 mcg/kg will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine 20 mcg/kg
Description: Once the third response to TOF is obtained, neostigmine 20 mcg/kg will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine 30 mcg/kg
Description: Once the third response to TOF is obtained, neostigmine 30 mcg/kg will be administered

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once the third response to TOF is obtained, saline will be administered
Study: NCT06110676

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LZM012
Description: Recombinant anti-human IL-17A/F humanized monoclonal antibody injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LZM012
Description: Recombinant anti-human IL-17A/F humanized monoclonal antibody injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Cosentyx
Study: NCT04824612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation with blue led
Description: Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month. blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Hexacetonide
Description: intralesional injection of 20 mg/ml. two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Triamcinolone Hexacetonide
Description: intralesional injection of 20 mg/ml. two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LED
Description: A blue LED without power and biologic effect.
Study: NCT06641245

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: folic acid (0.6 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-MTHF (5-methyltetrahydrofolate)
Description: 0.625 mg/d (6S)-5-MTHF